Questões de Concurso Comentadas por alunos sobre advérbios e conjunções | adverbs and conjunctions em inglês

Foram encontradas 359 questões

Resolva questões gratuitamente!

Junte-se a mais de 4 milhões de concurseiros!

www.qconcursos.com
Q2254454
Inglês Advérbios e conjunções | Adverbs and conjunctions ,
Ano: 2006 Banca: FCC Órgão: BACEN Prova: FCC - 2006 - BACEN - Analista do Banco Central - Área 3 - Conhecimentos Específicos |
Q2254454 Inglês
Senate Passes Plan to Cut $35 Billion From Deficit

By Jonathan Weisman
Washington Post Staff Writer
Friday, November 4, 2005; A01

    The Senate approved sweeping deficit-reduction legislation last night that would save about $35 billion over the next five years by cutting federal spending on prescription drugs, agriculture supports and student loans, while clamping down on fraud in the Medicaid program.
     The measure would also open Alaska's Arctic National Wildlife Refuge to oil drilling, a long-sought goal of the oil industry that took a major step forward after years of political struggle. A bipartisan effort to strip the drilling provision narrowly failed.
    The Senate bill, which passed 52 to 47, is the first in nearly a decade to tackle the growth of entitlement spending, the part of the federal budget that rises automatically based on set formulas and population changes.
     It would shave payments to some farmers by 2.5 percent, while eliminating a major cotton support program and trimming agriculture conservation spending. A proposal to limit payments to rich farmers failed yesterday. The measure passed largely along party lines, with only two Democrats voting for it and five Republicans voting against it.
     Yesterday's action is part of an effort by congressional Republicans to demonstrate fiscal discipline after widespread complaints of profligate spending on Capitol Hill. ....51.... many Democrats and some moderate Republicans are concerned that the effort may go too far, prominent Republicans in the Senate and House said the cuts were necessary to slow the rate of spending and control a deficit projected to total $314 billion by the end of the fiscal year.
      During a speech yesterday, former House majority leader Tom Delay (R-Tex) repeatedly apologized for excessive spending by Congress, including recent highway legislation that was ....52.... with lawmakers’ pet projects. After noting that House Republicans have voted to cut taxes every year since winning the majority in 1994, DeLay acknowledged, “Our record on spending has not been as consistent, ....53.... .”

(Adapted from washingtonpost.com)
Na questão, a palavra que preenche corretamente a lacuna é
Alternativas
Q2254265
Inglês Advérbios e conjunções | Adverbs and conjunctions ,
Ano: 2006 Banca: FCC Órgão: BACEN Provas: FCC - 2006 - BACEN - Analista do Banco Central - Área 1 - Prova 2 - Conhecimentos Específicos | FCC - 2006 - BACEN - Analista do Banco Central - Área 2 - Conhecimentos Específicos |
Q2254265 Inglês
The Internet at Risk

    Some 12,000 people convened last week in Tunisia for a United Nations conference about the Internet. Many delegates want an end to the U.S. Commerce Department's control over the assignment of Web site addresses (for example, http://www.washington-%20post.com/ ) and e-mail accounts (for example, [email protected]). The delegates' argument is that unilateral U.S. control over these domain names reflects no more than the historical accident of the Internet's origins. Why should the United States continue to control the registration of French and Chinese Internet addresses? It doesn't control the registration of French and Chinese cars, whatever Henry Ford's historic role in democratizing travel was.
    The reformers' argument is attractive in theory and dangerous in practice. In an ideal world, unilateralism should be avoided. But in an imperfect world, unilateral solutions that run efficiently can be better than multilateral ones that  ....51....
        The job of assigning domain names offers huge opportunities for abuse. ....52.... controls this function can decide to keep certain types of individuals or organizations offline (dissidents or opposition political groups, for example). Or it can allow them on in exchange for large fees. The striking feature of U.S. oversight of the Internet is that such abuses have not occurred.
        It's possible that a multilateral overseer of the Internet might be just as efficient. But the ponderous International Telecommunication Union, the U.N. body that would be a leading candidate to take over the domain registry, has a record of resisting innovation - including the advent of the Internet. Moreover, a multilateral domain-registering body would be caught between the different visions of its members: on the one side, autocratic regimes such as Saudi Arabia and China that want to restrict access to the Internet; on the other side, open societies that want low barriers to entry. These clashes of vision would probably make multilateral regulation inefficiently political. You may say that this is a fair price to pay to uphold the principle of sovereignty. If a country wants to keep certain users from registering domain names (Nazi groups, child pornographers, criminals), then perhaps it has a right to do so. But the clinching argument is that countries can exercise that sovereignty to a reasonable degree without controlling domain names. They can order Internet users in their territory to take offensive material down. They can order their banks or credit card companies to refuse to process payments to unsavory Web sites based abroad. Indeed, governments' ample ability to regulate the Internet has already been demonstrated by some of the countries pushing for reform, such as authoritarian China. The sovereign nations of the world have no need to wrest control of the Internet from the United States, because they already have it.

(Adapted from Washington Post, November 21, 2005; A14)
Ainda no primeiro parágrafo, os dois períodos Why should the United States continue to control the registration of French and Chinese Internet addresses? e It doesn't control the registration of French and Chinese cars, whatever Henry Ford's historic role in democratizing travel was. podem ser ligadas, sem alteração de sentido, pela conjunção
Alternativas
Q2244808
Inglês Advérbios e conjunções | Adverbs and conjunctions , Advérbios de: lugar, modo, tempo e freqüência | Adverbs of: place, manner, time and frequency ,
Ano: 2003 Banca: FCC Órgão: CVM Prova: FCC - 2003 - CVM - Inspetor |
Q2244808 Inglês

The hard cell

Thanks to politics, stem cell research in the United States is suffering. But not so in Sweden, which is poised to capture what could be the biggest new market to hit biotech in a decade.

By Stephan Herrera

February 13, 2003


New York, January 1, 2006:

Sweden announces that one of its biotechnology companies is the first in the world to enter clinical trials with a new drug that could cure Alzheimer's disease. Four years ago this type of research was all but stopped in the United States by political and ethical questions − which is ...61... Sweden now seems in the best position to capture a $25 billion market.


        Any day now, the U.S. Congress is expected to pass a sweeping new law that could dramatically inhibit researchers from working with stem cells taken from human embryos. Such cells, which can be used to grow a whole host of new cells and organs, could fundamentally change the way we treat heretofore intractable maladies like Alzheimer's disease, Parkinson's disease, cancer, stroke, liver failure, and heart disease. The only problem is that these cells by definition are derived from human embryos, many of which are cloned or come from unused fetuses collected at fertility clinics. The argument, from a certain segment of the American political spectrum, is that ...62... methods are morally wrong. They are ...63... a form of abortion or an activity that could eventually lead to human cloning.

             Those working in stem cell research say the short-term effect of the legislation will be to further chill all forms of scientific inquiry and commercialization efforts in the field. Entrepreneurs and investors are already eschewing such research − in large part because of the additional uncertainty and risk that politics introduce.

         Of the nearly 50 private stem cell companies in the United States, only a handful are still viable. Meanwhile, across the Atlantic, Sweden has avoided many of the political and ethical quagmires surrounding this type of research. It currently has 40 private stem cell companies, a number that's growing. Sweden's leading research universities have 32 percent of the world's stem cell inventory, close on the heels of the United States' 35 percent.

          Sweden, say analysts, is now in the best position to capture a worldwide market for drugs based on stem cell therapies that could grow to $25 billion in the next three to five years − nearly equal to the whole biotech industry at present. This estimate doesn't even address the market for stem cells capable of repairing damaged vital organs like the brain, heart, and kidneys. If the United States offers an object lesson of what can happen when scientific inquiry and investment capital fall victim to politics, Sweden and its leading stem cell startup, NeuroNova, offer the opposite example. How odd that the United States, which for generations has been the envy of the world for its progressive views of science and commercialization, should now have a biomedical climate chillier than a Swedish winter.

         One company feeling a lot of pain is StemCells, which at first glance seems to have it all: founding scientists include Stanford's Dr. Weissman and Fred Gage of the Salk Institute in La Jolla, California. An equally well-regarded expert in the treatment of Alzheimer's, Dr. Gage spent five years in Sweden as a researcher and now sits on a national committee on stem cell research there. The firm's chairman is Roger Perlmutter, Amgen's head of research.

       Yet over the past two years, none of management's efforts to help investors and even critics reconsider the stem cell field have worked. At press time, the stock was thinly traded and sitting in the neighborhood of 50 cents. With less than $15 million in cash, the company likely won't exist at this time next year. (CEO Martin McGlynn, who joined the firm in January 2001, would not talk to Red Herring, despite repeated efforts.)       

      Some observers on Wall Street are asking, If StemCells can't make it, who can? Geron, the only other publicly held stem cell firm to speak of, is in a fix, too. The company's stock price is also moribund, at $3.85 per share. Thanks to some capital infusions a few years ago, when money came easy, Geron still has $40 million on hand, but by the end of next year, that too will likely be gone. Once a media darling, Geron focuses on diagnostic tests and drugs derived from stem cells, a strategy that's not going well. For the nine months ended last September, revenue fell 68 percent to $955,000 and net loss widened 18 percent to $26.7 million. The company's financials were also hit hard after it terminated an agreement with Pharmacia and acquired research technology from Lynx Therapeutics, which Geron bought in a desperate attempt to be seen as something more than just a stem cell company.

     The situation is quite different, however, for Sweden's NeuroNova, which has 30 academic partners and a staff of 20. NeuroNova is working on ways to inject stem cells into the human brain to trigger a process called neurogenesis (the growth of new neural cells), which could combat diseases like Parkinson's, Alzheimer's, and even schizophrenia.

      If NeuroNova is the first to develop a drug capable of treating one of several central nervous system disorders − by far the most lucrative after heart disease products − it will have done so not because it raised more money or got more media buzz than the rest. It will have succeeded because the science is solid, and academe, government, and the investment community are supportive. Meanwhile, the United States will look on with envy and wonder how it, a country known for its entrepreneurial innovation, ever got so short-sighted.


(Adapted from http://www.redherring.com/investor/2003/02/biotech021303.html)

Para responder à questão, assinale, na folha de respostas, a letra correspondente a alternativa que preenche corretamente a lacuna do texto apresentado (...63...) .
Alternativas
Q2243757
Inglês Advérbios e conjunções | Adverbs and conjunctions , Advérbios de: lugar, modo, tempo e freqüência | Adverbs of: place, manner, time and frequency ,
Ano: 2003 Banca: FCC Órgão: CVM Prova: FCC - 2003 - CVM - Analista - Normas Contábeis e de Auditoria |
Q2243757 Inglês
      Michael R. Bloomberg is the 108th Mayor of the City of New York. He was born on February 14, 1942 to middle class parents in Medford, Massachusetts, where his father was the bookkeeper at a local dairy. Mayor Bloomberg's thirst for information and fascination with technology was evident at an early age, and led him to Johns Hopkins University, where he parked cars and took out loans to finance his education. After his college graduation, he gained an MBA from Harvard and in the summer of 1966, he was hired by Salomon Brothers to work on Wall Street.

    He quickly advanced through the ranks, and became a partner in 1972. Soon after, he was supervising all of Salomon's stock trading, sales and later, its information systems. He was fired in 1981 after another company acquired Salomon. Michael Bloomberg used his stake from the Salomon sale to start his ...39... company, an endeavor that would revolutionize the way that Wall Street ....40.... business. As a young trader, he had been amazed at the archaic nature in which information was stored. When he needed to see how a stock had been trading three weeks earlier, he had to find a copy of the Wall Street Journal from the date in question, and the records system consisted of clerks penciling trades in oversize ledgers. ...41... , he created a financial information computer that would collect and analyze different combinations of past and present securities data and deliver it immediately to the user.

       In 1982, Bloomberg LP sold 20 subscriptions to its service; 20 years ....42... , Bloomberg LP has over 165,000 subscribers worldwide. As the business proved its viability, the company branched out and in 1990 Bloomberg LP entered the media business, launching a news service, and then radio, television, Internet, and publishing operations.
   
         Nearly 20 years after its founding, Bloomberg LP now employs more than 8,000 people − including 2,500 in New York City − in more than 100 offices worldwide. As the company enjoyed tremendous growth, Michael Bloomberg dedicated more of his time and energy to philanthropy and civic affairs. His desire to improve education, advance medical research and increase access to the arts, has provided the motivation for much of his philanthropy.

         The Mayor served as the Chairman of the Board of Trustees of Johns Hopkins University until May 2002. Recently, he was honored by Johns Hopkins University, when its School of Hygiene and Public Health was renamed "The Bloomberg School of Public Health," a tribute to his leadership and use of philanthropy to improve the human ....43... .

     In 1997, Michael Bloomberg published his autobiography, Bloomberg by Bloomberg. All of the royalties from sales of the book are donated to the Committee to Protect Journalists.

(Adapted from http://home.nyc.gov/portal/index.jsp?pageID=nyc_mayor_bio&catID=119 4&cc=unused1196&rc=1194&ndi=-1)
Para responder à questão, assinale, na folha de respostas, a letra correspondente à alternativa que preencha corretamente a lacuna do texto apresentado (...42...). 
Alternativas
Q2242136
Inglês Advérbios e conjunções | Adverbs and conjunctions ,
Ano: 2003 Banca: FCC Órgão: CVM Prova: FCC - 2003 - CVM - Analista - Planejamento e Execução Financeira |
Q2242136 Inglês
The hard cell

The hard cell Thanks to politics, stem cell research in the United States is suffering. But not so in Sweden, which is poised to capture what could be the biggest new market to hit biotech in a decade.

By Stephan Herrera
February 13, 2003

New York, January 1, 2006:
Sweden announces that one of its biotechnology companies is the first in the world to enter clinical trials with a new drug that could cure Alzheimer's disease. Four years ago this type of research was all but stopped in the United States by political and ethical questions − which is ...61... Sweden now seems in the best position to capture a $25 billion market.

      Any day now, the U.S. Congress is expected to pass a sweeping new law that could dramatically inhibit researchers from working with stem cells taken from human embryos. Such cells, which can be used to grow a whole host of new cells and organs, could fundamentally change the way we treat heretofore intractable maladies like Alzheimer's disease, Parkinson's disease, cancer, stroke, liver failure, and heart disease. The only problem is that these cells by definition are derived from human embryos, many of which are cloned or come from unused fetuses collected at fertility clinics. The argument, from a certain segment of the American political spectrum, is that ....62... methods are morally wrong. They are ....63... a form of abortion or an activity that could eventually lead to human cloning.

      Those working in stem cell research say the short-term effect of the legislation will be to further chill all forms of scientific inquiry and commercialization efforts in the field. Entrepreneurs and investors are already eschewing such research − in large part because of the additional uncertainty and risk that politics introduce.

      Of the nearly 50 private stem cell companies in the United States, only a handful are still viable. Meanwhile, across the Atlantic, Sweden has avoided many of the political and ethical quagmires surrounding this type of research. It currently has 40 private stem cell companies, a number that's growing. Sweden's leading research universities have 32 percent of the world's stem cell inventory, close on the heels of the United States' 35 percent.

        Sweden, say analysts, is now in the best position to capture a worldwide market for drugs based on stem cell therapies that could grow to $25 billion in the next three to five years − nearly equal to the whole biotech industry at present. This estimate doesn't even address the market for stem cells capable of repairing damaged vital organs like the brain, heart, and kidneys. If the United States offers an object lesson of what can happen when scientific inquiry and investment capital fall victim to politics, Sweden and its leading stem cell startup, NeuroNova, offer the opposite example. How odd that the United States, which for generations has been the envy of the world for its progressive views of science and commercialization, should now have a biomedical climate chillier than a Swedish winter.

       One company feeling a lot of pain is StemCells, which at first glance seems to have it all: founding scientists include Stanford's Dr. Weissman and Fred Gage of the Salk Institute in La Jolla, California. An equally well-regarded expert in the treatment of Alzheimer's, Dr. Gage spent five years in Sweden as a researcher and now sits on a national committee on stem cell research there. The firm's chairman is Roger Perlmutter, Amgen's head of research.

    Yet over the past two years, none of management's efforts to help investors and even critics reconsider the stem cell field have worked. At press time, the stock was thinly traded and sitting in the neighborhood of 50 cents. With less than $15 million in cash, the company likely won't exist at this time next year. (CEO Martin McGlynn, who joined the firm in January 2001, would not talk to Red Herring, despite repeated efforts.)

      Some observers on Wall Street are asking, If StemCells can't make it, who can? Geron, the only other publicly held stem cell firm to speak of, is in a fix, too. The company's stock price is also moribund, at $3.85 per share. Thanks to some capital infusions a few years ago, when money came easy, Geron still has $40 million on hand, but by the end of next year, that too will likely be gone. Once a media darling, Geron focuses on diagnostic tests and drugs derived from stem cells, a strategy that's not going well. For the nine months ended last September, revenue fell 68 percent to $955,000 and net loss widened 18 percent to $26.7 million. The company's financials were also hit hard after it terminated an agreement with Pharmacia and acquired research technology from Lynx Therapeutics, which Geron bought in a desperate attempt to be seen as something more than just a stem cell company.

     The situation is quite different, however, for Sweden's NeuroNova, which has 30 academic partners and a staff of 20. NeuroNova is working on ways to inject stem cells into the human brain to trigger a process called neurogenesis (the growth of new neural cells), which could combat diseases like Parkinson's, Alzheimer's, and even schizophrenia.

       If NeuroNova is the first to develop a drug capable of treating one of several central nervous system disorders − by far the most lucrative after heart disease products − it will have done so not because it raised more money or got more media buzz than the rest. It will have succeeded because the science is solid, and academe, government, and the investment community are supportive. Meanwhile, the United States will look on with envy and wonder how it, a country known for its entrepreneurial innovation, ever got so short-sighted.

(Adapted from
http://www.redherring.com/investor/2003/02/biotech021303.html)

Instruções: Para responder a questão, assinale, na folha de respostas, a letra correspondente a alternativa que preenche corretamente a lacuna do texto apresentado.
Alternativas
Respostas
31: D
32: D
33: B
34: D
35: D
www.qconcursos.com